Author

B. A. Leeper

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:ChIP-seq· 1 Approach:experimental assay· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

D. E. Root· 2 shared K. Stegmaier· 2 shared P. C. Gokhale· 2 shared A. J. Murphy· 1 shared A. L. Christie· 1 shared A. L. Hong· 1 shared A. Raimondi· 1 shared B. Adane· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. E. Root

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

Y. Huang, R. T. Durall, N. M. Luong, H. J. Hertzler, J. Huang, P. C. Gokhale, B. A. Leeper, N. S. Persky, D. E. Root, P. V. Anekal, P. D. Montero Llopis, C. N. David, J. L. Kutok, A. Raimondi, K. Saluja, , C. A. French

This study identifies EZH2 as a dependency in NUT carcinoma, showing that combining EZH2 and BET inhibitors synergistically blocks tumor growth and prolongs survival.

bioRxiv · Aug 15, 2023Cancer Biology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology